<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-RNC-17012799</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-09-26</date_registration>
      <primary_sponsor>University-Town Hospital of Chongqing Medical University</primary_sponsor>
      <public_title>To investigate the pathogenesis of intrauterine adhesion and the mechanism of amniotic mesenchymal stem cells in the treatment of intrauterine adhesion.</public_title>
      <acronym />
      <scientific_title>To investigate the pathogenesis of intrauterine adhesion and the mechanism of amniotic mesenchymal stem cells in the treatment of intrauterine adhesion.</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-10-10</date_enrolment>
      <type_enrolment />
      <target_size>normal group, adhesion group:80;normal group, model group, transplantation group 1, transplantation group 2:80;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=21867</url>
      <study_type>Relative factors research</study_type>
      <study_design>Cohort study</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Intrauterine adhesions </hc_freetext>
      <i_freetext>normal group, adhesion group:without amniotic mesenchymal stem cells;normal group, model group, transplantation group 1, transplantation group 2:amniotic mesenchymal stem cells;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Xinpei Chen</firstname>
        <middlename />
        <lastname />
        <address>55 Daxuecheng Middle Road, Shapingba District, Chongqing, China </address>
        <city />
        <country1 />
        <zip>401331</zip>
        <telephone>+86 15178814645</telephone>
        <email>952731076@qq.com</email>
        <affiliation>University-Town Hospital of Chongqing Medical University </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Jia Wang</firstname>
        <middlename />
        <lastname />
        <address>55 Daxuecheng Middle Road, Shapingba District, Chongqing, China </address>
        <city />
        <country1 />
        <zip>401331</zip>
        <telephone>+86 13508307321</telephone>
        <email>752203031@qq.com</email>
        <affiliation>University-Town Hospital of Chongqing Medical University </affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Endometrium: 
(1) Meet the diagnostic criteria of intrauterine adhesions in the American reproductive association;
(2) The serum sex hormone levels was in the normal range;
(3) Did not receive any sex hormone therapy 3 months before the examination.
2. Placenta: Normal term selective cesarean section, no infectious disease, amniotic fluid, maternal voluntary to give up and donate the scientific research of abandoned placenta. </inclusion_criteria>
      <agemin />
      <agemax />
      <gender>Female</gender>
      <exclusion_criteria>1. Endometrium: Exclude endometriosis, uterine fibroids, habitual abortion, breast cancer, endometrial cancer, osteoporosis, thyroid disease, trigeminal neuralgia, certain medical diseases such as adrenal gland and other endocrine diseases, congenital disease;
2. Placenta: Exclude age less than 18 years old or above 40 years old, suffering from infectious diseases such as hepatitis B, hepatitis C, syphilis, AIDS, gonorrhea and other, suffering from severe maternal disease (such as intrahepatic cholestasis, fetal distress, placenta implantation). </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>functional gene;cell marker;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>2.The Medical Research Project of Chongqing (NO. 20141014) ; 2.The Medical specialty construction project of Chongqing (NO. 2013-46) </source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-12-30</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>